Pearl Huang, PhD

Pearl S. Huang joined Cygnal Therapeutics in January 2019 as President and CEO. She is also a venture partner at Flagship Pioneering and a member of the board of Cygnal Therapeutics.

Prior to Cygnal, Pearl served as Senior Vice President and Global Head of Therapeutic Modalities at Roche where she oversaw the discovery of biologic, small molecule, and nucleic acid-based therapies. She previously held several other senior roles within the pharmaceutical industry, including Vice President and Global Head of Discovery Academic Partnerships at GSK. In 2010, she founded BeiGene and served as Chief Scientific Officer until 2012, developing the company’s initial drug discovery pipeline and moving the company’s first programs into the clinic. From 2006 to 2010, Pearl was Vice President, Oncology Integrator of Discovery and Early development at Merck, leading 14 early development teams and conducting seven first-in-human trials in one year. Before joining Merck, Pearl lead oncology discovery at GSK where she helped initiate programs that delivered tramentinib and dabrafenib to patients.

Pearl received her undergraduate degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular biology from Princeton University.

Pearl Huang, PhD headshot

Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.